As per this report, the size of the Global Lung Cancer Therapeutics Market is expected to worth USD 6.43 billion in 2019 and estimated to be growing at a CAGR of 6.7%, to reach USD 8.89 billion by 2024.
Lung cancer is the second most commonly detected and has the highest death rate of all cancers in both men and women. Cigarette smoking is the projecting cause of lung cancer.
Lung cancer is a malignant tumor regarded as an uninhibited growth of cell tissues in the lung. Lung cancer declines the lung capability to deliver oxygen to the bloodstream. Some of the key indications of lung cancer comprise of appetite loss, wheezing, weight loss, coughing, mucus, shortness of breath, and chest pain.
Increasing occurrences of lung cancer because of the mounting smoking population is one of the major factors driving the growth of the global lung cancer therapeutics market. Additionally, the introduction of superior-priced drugs and new advanced radiation therapies are the major drivers fuelling market growth. Novel and safer therapies could improve opportunities for the growth of the global lung cancer therapeutics market.
However, the devices require huge amounts for installation and maintenance to have accurate results which are remained as challenging factor for the Lung Cancer Therapeutics Market developers. A dearth of skilled persons in properly managing the systems in real-time applications is slowly impeding the growth of the market. Lack of standardization is one more attribute limiting the demand of the Global Lung Cancer Therapeutics Market.
Increasing investments in healthcare centers by government and also to promote quality treatment services is lucratively leveling up growth opportunities for the global lung cancer therapeutics market. Rise in the popularity of the treatment procedures through digital advertisements is lavishing the demand of the market. Also, growing disposable income in urban areas is merely prompting the growth rate of this market to the extent. Furthermore, the market is fuelled by on-going research on the development of new technologies in favor of the end-users. The emergence of the latest technology in radiation therapies is enhancing the growth rate of the market. The rise in the economy is well developed and developing countries globally is greatly influencing the demand of the Global Lung Cancer Therapeutics Market.
Key Happenings in this market in the recent past:
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Treatment Type and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca Plc and Sanofi-Aventi. |
The research report on the Global Lung Cancer Therapeutics Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.
Lung Cancer Therapeutics Market Analysis - By Treatment Type
By Treatment Type, Chemotherapy treatment type is growing at a faster rate form the past decade. The increasing success rate of chemotherapy due to the adoption of advanced technology is considered to be the primary factor for this segment to grow extensively. A rise in the demand for effective treatment procedures with less adverse effects is levelling up the growth of the Global Lung Cancer Therapeutics Market. Growing preference for early detection and diagnosis of the diseases is also surging the growth rate of the market. Stringent rules and regulations by the government in approving new products in concern towards people’s safety is elevating the demand for the global lung cancer therapeutics market.
Regional Analysis:
North America and Europe lead the global lung cancer therapeutics market. Lung cancer is the most common type of cancer in the U.S and the majority of the population die of lung cancer every year. Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market owing to the high occurrence of this disease along with growing healthcare alertness.
Companies are implementing various strategies to increase their product portfolio and raise their geographical presence. New product expansion, contracts, and associations, and procurements are some of the significant approaches adopted by the manufacturers in the lung cancer therapeutics market.
List of key market participants dominating the Global Lung Cancer Therapeutics Market profiled in this report are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Cisplatin
5.1.1.2 Taxol
5.1.1.3 Navelbine
5.1.1.4 Camptosar
5.1.1.5 Alimta
5.1.2 Radiotherapy
5.1.2.1 External Beam
5.1.2.2 Internal Beam
5.1.2.3 Systemic
5.1.3 Other Drugs
5.1.3.1 Abraxane
5.1.3.2 Avastin
5.1.3.3 Crizotinib
5.1.3.4 Docetaxel
5.1.3.5 Gefitinib
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 BoehringerIngelheim GmbH
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Hoffman-La Roche
9.3 Pfizer Inc.
9.4 GlaxoSmitKline
9.5 Eli Lilly and Company
9.6 AstrazenecaPlc
9.7 Sanofi-Aventis
9.8 Agennix AG
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
